These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36575841)

  • 1. Unraveling the Role of K
    Mondéjar-Parreño G
    Front Biosci (Schol Ed); 2022 Nov; 14(4):31. PubMed ID: 36575841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
    Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
    Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K
    Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D
    Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Populations of in silico myocytes and tissues reveal synergy of multiatrial-predominant K
    Ni H; Fogli Iseppe A; Giles WR; Narayan SM; Zhang H; Edwards AG; Morotti S; Grandi E
    Br J Pharmacol; 2020 Oct; 177(19):4497-4515. PubMed ID: 32667679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial-selective K
    Ravens U
    Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.
    Schmidt C; Wiedmann F; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Life Sci; 2014 Mar; 97(2):107-15. PubMed ID: 24345461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches for pharmacological management of atrial fibrillation.
    Ehrlich JR; Nattel S
    Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac K
    Staudacher I; Seehausen S; Illg C; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2019 Jul; 144():128-138. PubMed ID: 31182191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy.
    Wiedmann F; Beyersdorf C; Zhou XB; Kraft M; Paasche A; Jávorszky N; Rinné S; Sutanto H; Büscher A; Foerster KI; Blank A; El-Battrawy I; Li X; Lang S; Tochtermann U; Kremer J; Arif R; Karck M; Decher N; van Loon G; Akin I; Borggrefe M; Kallenberger S; Heijman J; Haefeli WE; Katus HA; Schmidt C
    Cardiovasc Res; 2022 Jun; 118(7):1728-1741. PubMed ID: 34028533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-Pore-Domain Potassium (K
    Wiedmann F; Frey N; Schmidt C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stretch-activated two-pore-domain (K
    Schmidt C; Wiedmann F; Kallenberger SM; Ratte A; Schulte JS; Scholz B; Müller FU; Voigt N; Zafeiriou MP; Ehrlich JR; Tochtermann U; Veres G; Ruhparwar A; Karck M; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2017 Nov; 130(Pt B):233-243. PubMed ID: 28526353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation: Therapeutic potential of atrial K
    Ravens U; Odening KE
    Pharmacol Ther; 2017 Aug; 176():13-21. PubMed ID: 27742566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ion channel targets in atrial fibrillation.
    Hancox JC; James AF; Marrion NV; Zhang H; Thomas D
    Expert Opin Ther Targets; 2016 Aug; 20(8):947-58. PubMed ID: 26918581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanosensitive TREK-1 two-pore-domain potassium (K
    Wiedmann F; Rinné S; Donner B; Decher N; Katus HA; Schmidt C
    Prog Biophys Mol Biol; 2021 Jan; 159():126-135. PubMed ID: 32553901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atria-selective antiarrhythmic drugs in need of alliance partners.
    Peyronnet R; Ravens U
    Pharmacol Res; 2019 Jul; 145():104262. PubMed ID: 31059791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Antiarrhythmic Drugs for Atrial Fibrillation.
    Saljic A; Heijman J; Dobrev D
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Ca
    Heijman J; Zhou X; Morotti S; Molina CE; Abu-Taha IH; Tekook M; Jespersen T; Zhang Y; Dobrev S; Milting H; Gummert J; Karck M; Kamler M; El-Armouche A; Saljic A; Grandi E; Nattel S; Dobrev D
    Circ Res; 2023 Apr; 132(9):e116-e133. PubMed ID: 36927079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological approaches in the treatment of atrial fibrillation.
    Tamargo J; Caballero R; Delpón E
    Curr Med Chem; 2004 Jan; 11(1):13-28. PubMed ID: 14754423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.